2. UroToday Home
  3. Tags

Target Alpha Therapy (TAT) Articles

Articles

  • ESMO 2017: Case Studies in mCRPC – Navigating the Increasingly Busy Waters

    Madrid, Spain (UroToday.com) Dr. Omlin and Dr. O’Sullivan provided several complex case presentations for patients with mCRPC at the Targeted Alpha Therapy in mCRPC lunch symposium. The first case was a 76-year-old presented by Dr. Omlin who was diagnosed with bone and lymph node metastases cT3bN2M1(bone), Gleason 5+5 disease, and PSA 39.1 ng/mL. He was initially started on ADT and denosumab, however within nine months his PSA was increasing in the setting of castrate testosterone and he was started on six weeks of docetaxel with a subsequent >50% PSA response.
    Published September 9, 2017

  • ESMO 2017: Panel Discussion – Targeted Alpha Therapy

    Madrid, Spain (UroToday.com) Professor Johann de Bono lead a panel discussion, alongside his panelists Drs. James, Omlin, and O’Sullivan, fielding questions from the audience at the Targeted Alpha Therapy in mCRPC lunch symposium. Several interesting questions were posed to the panel of experts:
    Published September 9, 2017

  • ESMO 2017: The Future of Targeted Alpha Therapy

    Madrid, Spain (UroToday.com) Professor Johann de Bono from the UK presented on the future of targeted alpha therapy. Dr. de Bono shared a comprehensive slide delineating the timeline of alpha-emitting radionuclide therapy in oncology, specifically highlighting radium-223 approval in mCRPC in 2013 and the first patient being treated with thorium-227 in 2016.  
    Published September 9, 2017

  • Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen).

    Radioligand therapy is a type of internal radiotherapy combining a short-range radioisotope labeled to a carrier with a high affinity for a specific receptor expressed on tumor cells. Targeted alpha therapy (TAT) combines a high-linear energy transfer (LET) emitter (225Ac) with a prostate-specific membrane antigen (PSMA) carrier, specifically binding tumor cells in patients with metastatic castration-resistant prostate cancer.
    Published December 2, 2020